StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $12.65 | $12.45 | -1.58% | 0.2M |
| 05-19 | $12.38 | $12.59 | +1.70% | 0.1M |
| 05-20 | $12.49 | $12.60 | +0.88% | 0.1M |
| 05-21 | $12.47 | $12.63 | +1.28% | 0.2M |
| 05-22 | $12.65 | $12.59 | -0.47% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. The company provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. The company is focused on offering talent to Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $76.04M | $385.79M | $310.69M | $221.28M |
Operating Income | $-3.29M | $-14.21M | $-6.41M | $-2.33M |
Net Income | $-2.12M | $-18.67M | $-553.00K | $2.48M |
EPS (Diluted) | $-0.19 | $-1.70 | $-0.05 | $0.15 |
Total Assets | $252.05M | $247.97M | $268.21M | $269.33M |
Total Liabilities | $54.37M | $49.05M | $53.50M | $53.33M |
Cash & Equivalents | $71.53M | $89.30M | $99.53M | $101.69M |
Free Cash Flow OCF − CapEx | $-836.00K | $1.25M | $7.88M | $-2.87M |
Shares Outstanding | 11.12M | 10.99M | 10.99M | 10.99M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.